Clinical Trial Update: Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes [Phase 2]

View source ↗

Summary

Results from a Phase 2 trial evaluating nivolumab in combination with talazoparib in patients with metastatic or unresectable melanoma carrying BRCA or BRCA-lik…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Talazoparib (Talzenna) (talazoparib)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Metastatic or Unresectable Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-14